

## Press Release

### **Chordia and Ono Pharmaceutical Enter into Exclusive License Agreement on CTX-177, a MALT1 Inhibitor, and Other Related Compounds**

**Kyoto, Japan, December 15, 2020** – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1<sup>st</sup> Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Ko Kusumi; “KYOTO-iCAP”), today announced that Chordia Therapeutics Inc. (Kanagawa, Japan; President and CEO, Hiroshi Miyake; “Chordia”) announced that it entered into a license agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) for CTX-177, Chordia’s MALT1 inhibitor, as well as its other related compounds.

Under the terms of the agreement, Chordia will grant exclusive rights to develop, manufacture and commercialize CTX-177 and other related compounds globally. Chordia will receive a one-time upfront payment and near-term development milestone totaling JPY3.3 billion (upfront JPY0.8 billion, and JPY2.5 billion at starting phase 1 clinical study), and up to an additional JPY49.6 billion if certain development and commercial milestones are achieved. Chordia is also eligible to receive high-single digits to low double-digit tiered royalties based on net global sales of CTX-177.

“We are excited to build a new partnership for our MALT1 inhibitor, CTX-177 with ONO, one of the leading pharmaceutical companies in oncology therapeutic area with innovative development and product portfolio.” said Hiroshi Miyake, President and CEO of Chordia. “I am delighted that our team was able to discover the selective and potent MALT1 inhibitor, CTX-177 through our dedicated efforts on pipeline assets with novel mode of actions. We are confident that this partnership will accelerate development of CTX-177 for cancer patients with unmet medical needs.”

“We are enthusiastic about that this license agreement will accelerate the research and development of the MALT1 inhibitor "CTX-177" and we would like to hope to be a new treatment option for cancer patients as soon as possible. In addition, MALT1 inhibitors were developed by industry-government-academia

efforts, including Kyoto University. KYOTO-iCAP considers that this initiative will be one of the models for creating innovation in Japan.” said Ko Kusumi, President and CEO of KYOTO-iCAP

### **About CTX-177**

CTX-177 is a selective inhibitor against a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which is known to be involved in an intracellular signaling pathway in lymphocytic blood cells. Activation of MALT1 is reported to play an important role in malignancies of lymphocytes. CTX-177 is expected to exert anti-tumor effect against these malignancies by inhibiting of MALT1 activity.

MALT1 program was initiated by the industry-government-academia research collaboration among Takeda Pharmaceutical Company Ltd. (Takeda), Kyoto University and University of

Miyazaki supported by research grant of Acceleration Transformative Research for Medical Innovation sponsored by Japan Agency for Medical Research and Development (AMED). Chordia obtained the license from Takeda and carries out its lead-optimization and then successfully discovered CTX-177. IND-enabling works were performed in the collaboration where National Cancer Center Japan joined and supported by AMED’s Practical Research for Innovative Cancer Control research grant. Preclinical data of CTX-177 was presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition held virtually on December 5 - 8, 2020. (Abstract #141824, Daisuke Morishita et.al. :Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas)

### **About Chordia Therapeutics Inc.**

Chordia Therapeutics Inc is an oncology drug discovery and development company focusing on advancing innovative assets to deliver transformative therapies to cancer patients since its foundation in November 2017 at Shonan Health Innovation Park, Kanagawa, Japan. Chordia’s lead asset CTX-712, a CLK inhibitor, is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer, and is expected to deliver benefit to patients of various types of cancer. Chordia has also multiple early-stage pipelines for targeting tumors with particular abnormalities. For additional info., please visit <https://www.chorditherapeutics.com>.

**About Kyoto University Innovation Capital Co., Ltd. (“Kyoto iCAP”)**

Kyoto iCAP is a wholly owned subsidiary of Kyoto University established in December 2014. Its purpose is to provide investment and support to companies founded by researchers belonging to Kyoto University (including spin-offs from joint research companies) for commercializing knowledge (including research results, technology, etc.). The KYOTO-iCAP 1<sup>st</sup> Fund was created from a 16-billion-yen capital contribution from Kyoto University and private financial institutions, in January 2016. KYOTO-iCAP is a general partner of the Fund. The fund management period is 15 years, that enables KYOTO-iCAP to support Kyoto University-originated ventures with long-term and to provide equity from the seed stage to practical application. The university is one of the top research institutions in Asia.

**【Contact Information】**

Kyoto University Innovation Capital Co., Ltd.

36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317 Japan

Kyoto University International Science Innovation Building, East Building, 4th Floor

Head of Media Relations: Osami Kono

Tel: +81-(0)75-753-5303, Fax: +81-(0)75-753-7592

Email: [info@kyoto-unicap.co.jp](mailto:info@kyoto-unicap.co.jp)

Contact

Chordia Therapeutic Inc.

[info@chorditherapeutics.com](mailto:info@chorditherapeutics.com)